|
|
|
 | ||
|
Dow Global Technologies Inc. Announces License Agreement with Serum Institute of India Limited Midland, Mich. - February 27, 2007 Dow Global Technologies Inc. today announced that Serum Institute of India Limited has entered into a commercial license agreement for Pfēnex Expression Technology™, a Pseudomonas-based technology from DowpharmaSM. The first product under the agreement is a confidential proprietary protein for which a high-yield production strain has already been developed by Dowpharma. Dowpharma will transfer the production strain to Serum Institute of India with full support for its regulatory filing. Under the agreement, which encompasses the use of the protein in future combination vaccine products, Serum Institute of India Limited. will have a license to use Pfēnex Expression Technology™ for the development and manufacture of vaccines at affordable prices across the globe. Dowpharma will receive an upfront licensing fee, maintenance & milestone fees and a royalty on product sales. “Our technologies continue to earn the confidence of the pharmaceutical industry and we are pleased to be working with Serum Institute of India to fulfill its future protein production needs as part of agreement,” said Nick Hyde, Global Business Director for DowpharmaSM. “Proteins produced by Pfēnex Expression Technology™ are now in human clinical trials and the system consistently delivers high quality protein faster than traditional expression systems.” Serum’s Senior Scientific Executive Director, Dr. S.V. Kapre noted “Dowpharma and Pfēnex Expression Technology™ were chosen because of Dow’s excellent record in rapidly developing and providing high-yielding Pfēnex Expression Technology™ production strains to help reduce our time to market and manufacturing costs.” Pfēnex Expression Technology™, a Pseudomonas fluorescens-based fermentation technology, includes an extensive toolbox of gene expression capabilities and multiple host strains. Combined with high-throughput methods, strains producing high levels of active, complex recombinant proteins such as antibody derivatives and fully-functional antigens and adjuvant proteins are rapidly constructed and identified. The production process contains no animal derived products and no antibiotics or antibiotic selection markers, making scale-up safe, efficient, and highly cost effective. About Pfēnex Expression Technology™ Using a natural isolate of Pseudomonas fluorescens, an abundant and non-infectious component of the microbial flora of soil, water, and plants, many high performance production strains have been developed. Proteins are expressed in high yields with correct disulfide bond formation, reduced proteolytic degradation and enhanced solubility/activity, making the process of strain development faster and more efficient than in traditional microbial expression host strain development. Dozens of host strains are tested in parallel to identify expression strategy/host cell combinations that result in improved target protein accumulation and/or stability. The technology is easily employed in traditional fermentation, recovery and purification settings with no need for additional, unique equipment. About the Serum Institute of India Limited Established in 1966, the Serum Institute of India is the world's largest producer of Measles and DTP group of vaccines, in addition to anti-venom, tetanus, and other vaccines. The goal of the company is to provide affordable vaccinations against a variety of diseases to all the children in the world. These products are presently used in 145 countries around the globe. More information at – www.seruminstitute.com About Dowpharma For information about Dowpharma visit www.dowpharma.com For Editorial Information: Mike Altmann |
||
|
Dow Home Privacy Statement Internet Disclaimer Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2008). All Rights Reserved. 
|
||